BCL2L1 and cancer: The new BH3 profiling-informed model of mitochondrial priming and anti-apoptotic dependencies in TIS cancer cells (Figure 2A) offers a mechanistic rationale for prioritizing BCL-xL-selective senolytics for clinical applications after TIS induction, particularly for tumors with transient senescence responses (e.g., palbociclib and olaparib TIS).